Glaxo, Vir Covid Therapy Endorsed by Regulator for EU Use
- EU regulator makes recommendations for use by member states
- Agency is also reviewing the treatment for a full approval
This article is for subscribers only.
A Covid-19 antibody treatment from GlaxoSmithKline Plc and Vir Biotechnology Inc. was endorsed by the European Union drug regulator for use in the region, clearing the way for another much-needed therapy.
The European Medicines Agency completed a review of the trial data and concluded the antibody -- VIR-7831 -- is a valid treatment option for adults and adolescents with a mild or moderate case who are at risk of the disease worsening, the regulator said Friday.